Pharmacist Menopause/Perimenopause | Patient Safety | Treatment Guidelines Podcast 45 credit minutes

Menopausal hormone therapy has long carried a boxed warning (formerly a “black box warning”) that may not accurately reflect the therapy’s risk-benefit profile for all patients. This course discusses the FDA’s recent removal of boxed warnings for select hormone therapy (HT) products, the rationale for this change, and how evolving guidance may impact patient care. You will explore strategies to support evidence-based counseling and individualized decision-making for patients considering HT.

Learning Objectives

Upon successful completion of this course, pharmacists should be able to:
1. Summarize the FDA’s updated position on boxed warnings for menopausal hormone therapy.
2. Identify key considerations for pharmacists when counseling patients about the benefits and risks of hormone therapy.

Faculty

Rachel Maynard, PharmD

GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

Disclosures:

Rachel Maynard has no relevant financial relationships with ineligible companies to disclose.

Erin Raney, PharmD, BCPS, BC-ADM

Professor
Midwestern University College of Pharmacy, Glendale Campus

Disclosures:

Erin Raney has no relevant financial relationships with ineligible companies to disclose.

Course Details